Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for kids with transplant complication

NCT ID NCT03774082

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete or partial response by 7 months. Results are still being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ruxolitinib (a drug taken by mouth to reduce inflammation)
What this could lead to
If successful, this could offer a new treatment option for children with chronic graft-versus-host disease, helping control the condition and reduce symptoms.
What could go wrong
This is a small, early-phase trial with no placebo group, so results are preliminary. Ruxolitinib may not work for all children and can have side effects like infections or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease follicular lymphoma graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE

Contacts and locations

Locations

  • Novartis Investigative Site

    São Paulo, 04039 001, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, M5G 1X8, Canada

  • Novartis Investigative Site

    Prague, 150 06, Czechia

  • Novartis Investigative Site

    Tamil Nadu, Chennai, 600035, India

  • Novartis Investigative Site

    Pune, Maharashtra, 411004, India

  • Novartis Investigative Site

    Bangalore, 560099, India

  • Novartis Investigative Site

    Delhi, 110 085, India

  • Novartis Investigative Site

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 466 8560, Japan

  • Novartis Investigative Site

    Saitama, 330 8777, Japan

  • Novartis Investigative Site

    Saint Petersburg, 197022, Russia

  • Novartis Investigative Site

    Bratislava, 833 40, Slovakia

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Zurich, CH - 8032, Switzerland

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Adana, 1330, Turkey (Türkiye)

  • Novartis Investigative Site

    Antalya, 07000, Turkey (Türkiye)

  • Novartis Investigative Site

    Antalya, 07070, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.